References

1. A Matthius and E Quinn, “Experts forecast cancer research and treatment advances in 2025” (2025). Available at: https://www.aacr.org/blog/2025/01/10/experts-forecast-cancer-research-and-treatment-advances-in-2025/
2. Grand View Research, “Oncology companion diagnostic market size report 2030.” Available at: https://www.grandviewresearch.com/industry-analysis/oncology-companion-diagnostics-market 
3. M Katoh et al., “Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules,” Front Mol Med, 5, 1661016 (2025). DOI: 10.3389/fmmed.2025.1661016. 
4. B Nolting, “Linker technologies for antibody-drug conjugates,” Methods Mol Biol, 1045, 71-100 (2013). DOI: 10.1007/978-1-62703-541-5_5.
5. J He et al., “Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies,” MedComm, 5, 8, e671 (2020). DOI: 10.1002/mco2.671. PMID: 39070179.
6. B Chen et al, “Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions,” Mol Cancer, 24, 1, 279 (2025). DOI: 10.1186/s12943-025-02489-2. 
7. L Incorvaia et al., “Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC), Adv Ther, 36, 10, 2600-2617 (2019). DOI: 10.1007/s12325-019-01057-7.
8. AstraZeneca, “ Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial” (2024). Available at: https://www.astrazeneca.com/media-centre/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial.html